Orforglipron
GLP-1 (small molecule) · oral · Eli Lilly
Summary
- Also known as
- LY3502970
- Mechanism
- GLP-1 (small molecule)
- Route
- oral
- Company
- Eli Lilly
- Highest development stage
- approved
- Status (as of data cut)
- Approved in the US for obesity (Foundayo, 2026); T2D phase 3 positive (ACHIEVE) verify
- Next milestone
- T2D filing; CV outcomes trial ongoing
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 4 approved / in label | FDA: Foundayo (2026) | Foundayo US label (2026); ATTAIN-1 |
| T2D | 3 positive phase 3 | Positive phase 3 programme (ACHIEVE); not yet labelled for T2D | ACHIEVE-1; ACHIEVE-4 (EASD 2026) |
| CV outcomes | 3 positive phase 3 | ACHIEVE-4 met MACE non-inferiority versus insulin glargine; a placebo-controlled CV outcomes trial is ongoing | ACHIEVE-4 (EASD 2026); CVOT (ongoing) |
| CKD | 1 phase 2 / signal | Slower eGFR decline versus glargine as a secondary outcome in ACHIEVE-4 | ACHIEVE-4 kidney outcomes (EASD 2026) |
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 3 positive phase 3 | Positive phase 3: ATTAIN-OSA (JAMA, Nov 2026) | ATTAIN-OSA, JAMA 2026; ATTAIN-OSA |
| Knee OA | 2 phase 3 ongoing | Phase 3 ongoing | |
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
US prescribing information: indications
Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.
FOUNDAYO US label 29.07.2026
1 INDICATIONS AND USAGE FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACHIEVE-1 | orforglipron 36 mg | t2d | 40 | 559 | −7.9 % vs −1.6 % Δ −6.3 pp | −7.6 % vs −1.7 % Δ −5.9 pp | −1.5 vs −0.4 | 7.8 vs 1.4 | 9.9 vs 7.2 | 16.3 vs 2.2 | 14.2 vs 1.4 | 2.8 vs 3.6 | — | verified |
| ACHIEVE-2 (vs dapagliflozin) | orforglipron 3 mg vs dapagliflozin 10 mg (active) | t2d | 40 | 240 | — | —−3.5 % estimand not specified | −1.3 | — | — | 19.6 | 7.9 | 3.3 | — | verified |
| ACHIEVE-2 (vs dapagliflozin) | orforglipron 12 mg vs dapagliflozin 10 mg (active) | t2d | 40 | 241 | — | —−6.3 % estimand not specified | −1.7 | — | — | 17.8 | 8.3 | 5.8 | — | verified |
| ACHIEVE-2 (vs dapagliflozin) | orforglipron 36 mg vs dapagliflozin 10 mg (active) | t2d | 40 | 241 | — | —−7.3 % estimand not specified | −1.7 | — | — | 22.4 | 12.0 | 4.1 | — | verified |
| ACHIEVE-4 (vs insulin glargine) | orforglipron 36 mg or MTD vs insulin glargine (active) | t2d | 52 | — | −8.8 % | −7.8 % | −1.5 | 15.4 | 30.9 vs 20.5 | 31.9 | 21.0 | 16.2 | — | verified |
| ATTAIN-1 | orforglipron 36 mg | obesity | 72 | 3127 | −12.4 % vs −0.9 % Δ −11.5 pp | −11.2 % vs −2.1 % Δ −9.1 pp | — | 10.3 vs 2.7 | 24.4 vs 29.9 | — | — | 3.8 vs 4.9 | — | verified |
| ATTAIN-2 (obesity + T2D) | orforglipron 6 mg | t2d | 72 | 1613 | −5.5 % vs −2.2 % Δ −3.3 pp | −5.1 % vs −2.5 % Δ −2.6 pp | −1.2 vs −0.5 | 6.1 vs 4.6 | 19.1 vs 20.0 | 20.1 vs 8.4 | 12.8 vs 3.8 | 7.3 vs 8.8 | — | verified |
| ATTAIN-2 (obesity + T2D) | orforglipron 12 mg | t2d | 72 | 1613 | −7.8 % vs −2.2 % Δ −5.6 pp | −7.0 % vs −2.5 % Δ −4.5 pp | −1.5 vs −0.5 | 10.6 vs 4.6 | 22.3 vs 20.0 | 31.1 vs 8.4 | 20.2 vs 3.8 | 10.3 vs 8.8 | — | verified |
| ATTAIN-2 (obesity + T2D) | orforglipron 36 mg | t2d | 72 | 1613 | −10.5 % vs −2.2 % Δ −8.3 pp | −9.6 % vs −2.5 % Δ −7.1 pp | −1.7 vs −0.5 | 10.6 vs 4.6 | 20.5 vs 20.0 | 36.4 vs 8.4 | 23.1 vs 3.8 | 10.9 vs 8.8 | — | verified |
| ATTAIN-J (Japan) | orforglipron 6 mg | obesity | 72 | 61 | — | −5.9 % vs −0.6 % Δ −5.3 pp | — | — | — | — | — | — | — | verified |
| ATTAIN-J (Japan) | orforglipron 12 mg | obesity | 72 | 57 | — | −8.7 % vs −0.6 % Δ −8.1 pp | — | — | — | — | — | — | — | verified |
| ATTAIN-J (Japan) | orforglipron 36 mg | obesity | 72 | 60 | — | −7.9 % vs −0.6 % Δ −7.3 pp | — | — | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- orforglipron 6 mg: 329 of 1613 participants randomised to this arm (placebo 630). HbA1c: treatment-regimen estimand (Table 2). Any discontinuation = participants who discontinued the intervention / randomised (Figure 1). Systolic blood pressure is reported by dose only in a figure panel and is not shown.
- orforglipron 12 mg: 332 of 1613 participants randomised to this arm (placebo 630). HbA1c: treatment-regimen estimand (Table 2). Any discontinuation = participants who discontinued the intervention / randomised (Figure 1). Systolic blood pressure is reported by dose only in a figure panel and is not shown.
- orforglipron 36 mg: 322 of 1613 participants randomised to this arm (placebo 630). HbA1c: treatment-regimen estimand (Table 2). Any discontinuation = participants who discontinued the intervention / randomised (Figure 1). Systolic blood pressure is reported by dose only in a figure panel and is not shown.
- orforglipron 36 mg: Any discontinuation = 100 − % continuing the drug to week 40.
- orforglipron 36 mg or MTD: Active comparator insulin glargine: weight +1.66 % (efficacy) / +1.12 % (treatment-policy), HbA1c −0.96, AE discontinuation 5.4 %, nausea 1.4 %, vomiting 1.6 %, SAE 18.8 %. Safety and discontinuation cover the whole on-treatment period (to week 104 or later); any discontinuation derived from «completed on treatment».
- orforglipron 3 mg: Active comparator dapagliflozin 10 mg: HbA1c -0.76, weight -3.0 %, AE withdrawal 0.0 %, nausea 1.7 %, vomiting 1.7 %, SAE 4.6 %. Estimand not stated in the registry record. AE discontinuation of the study drug is not reported; the registry gives withdrawal from the study for adverse events (not shown on the axis).
- orforglipron 12 mg: Active comparator dapagliflozin 10 mg: HbA1c -0.76, weight -3.0 %, AE withdrawal 0.0 %, nausea 1.7 %, vomiting 1.7 %, SAE 4.6 %. Estimand not stated in the registry record. AE discontinuation of the study drug is not reported; the registry gives withdrawal from the study for adverse events (not shown on the axis).
- orforglipron 36 mg: Active comparator dapagliflozin 10 mg: HbA1c -0.76, weight -3.0 %, AE withdrawal 0.0 %, nausea 1.7 %, vomiting 1.7 %, SAE 4.6 %. Estimand not stated in the registry record. AE discontinuation of the study drug is not reported; the registry gives withdrawal from the study for adverse events (not shown on the axis).
- orforglipron 6 mg: Japanese adults with obesity disease (BMI 27 to <35 with ≥2 or ≥35 with ≥1 obesity-related disorder; ~25 % with T2D). Abstract only so far: treatment-regimen weight change; AE discontinuation, nausea and vomiting await the full text.
- orforglipron 12 mg: Japanese adults with obesity disease (BMI 27 to <35 with ≥2 or ≥35 with ≥1 obesity-related disorder; ~25 % with T2D). Abstract only so far: treatment-regimen weight change; AE discontinuation, nausea and vomiting await the full text.
- orforglipron 36 mg: Japanese adults with obesity disease (BMI 27 to <35 with ≥2 or ≥35 with ≥1 obesity-related disorder; ~25 % with T2D). Abstract only so far: treatment-regimen weight change; AE discontinuation, nausea and vomiting await the full text.
Verbatim quotes from the source (62)
- orforglipron 36 mg · weight_eff · Figure 1B (garbled text; arm mapping inferred from ETDs)
−7.8 −12.4 −0.9 −9.3 ETD, −11.5 percentage points (95% CI, −12.3 to −10.6) ETD, −8.4 percentage points (95% CI, −9.2 to −7.6) ETD, −6.9 percentage points
- orforglipron 36 mg · weight_tp · Table 2
−7.5 (−8.2 to −6.8) −8.4 (−9.1 to −7.7) −11.2 (−12.0 to −10.4) −2.1 (−2.8 to −1.4)
- orforglipron 36 mg · ae_dc · Table 4
Any adverse event 38 (5.3) 57 (7.9) 75 (10.3) 26 (2.7) 196 (6.3)
- orforglipron 36 mg · disc_any · Results, Patients; computed from 552 (75.6%) of 730 continui
the percentage of patients who discontinued treatment for any reason was 25.0% (21.9 to 24.4% in the orforglipron groups and 29.9% in the placebo group)
- orforglipron 36 mg · sae · Table 4
Serious adverse event 40 (5.5) 39 (5.4) 28 (3.8) 46 (4.9) 153 (4.9)
- orforglipron 6 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
the mean percent change in bodyweight from baseline to week 72 was –5·1% (95% CI –6·0 to –4·2) with 6 mg (estimated treatment difference [ETD] –2·7 [95% CI –3·7 to –1·6]; p<0·0001)
- orforglipron 6 mg · weight_eff · Results, efficacy estimand (figure 2B)
For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
- orforglipron 6 mg · ae_dc · Table 4
Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
- orforglipron 6 mg · disc_any · Figure 1 trial profile; computed: 63/329 vs 126/630 with placebo
63 discontinued intervention
- orforglipron 6 mg · nausea · Table 4
Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
- orforglipron 6 mg · vomiting · Table 4
Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
- orforglipron 6 mg · sae · Table 4
Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
- orforglipron 6 mg · hba1c · Table 2
Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
- orforglipron 12 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
–7·0% (–7·8 to –6·2) with 12 mg (ETD –4·5 [–5·5 to –3·6]; p<0·0001)
- orforglipron 12 mg · weight_eff · Results, efficacy estimand (figure 2B)
For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
- orforglipron 12 mg · ae_dc · Table 4
Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
- orforglipron 12 mg · disc_any · Figure 1 trial profile; computed: 74/332 vs 126/630 with placebo
74 discontinued intervention
- orforglipron 12 mg · nausea · Table 4
Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
- orforglipron 12 mg · vomiting · Table 4
Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
- orforglipron 12 mg · sae · Table 4
Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
- orforglipron 12 mg · hba1c · Table 2
Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
- orforglipron 36 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
–9·6% (–10·5 to –8·7) with 36 mg orforglipron (ETD –7·1 [–8·2 to –6·1]; p<0·0001)
- orforglipron 36 mg · weight_eff · Results, efficacy estimand (figure 2B)
For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
- orforglipron 36 mg · ae_dc · Table 4
Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
- orforglipron 36 mg · disc_any · Figure 1 trial profile; computed: 66/322 vs 126/630 with placebo
66 discontinued intervention
- orforglipron 36 mg · nausea · Table 4
Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
- orforglipron 36 mg · vomiting · Table 4
Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
- orforglipron 36 mg · sae · Table 4
Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
- orforglipron 36 mg · hba1c · Table 2
Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
- orforglipron 36 mg · weight_eff · Figure 2B (end-of-curve labels, efficacy estimand; garbled o
−4.7% (−4.4 kg) −7.9% (−7.3 kg) −1.6% (−1.3 kg) −6.1% (−5.5 kg)
- orforglipron 36 mg · weight_tp · Results, End Points paragraph; Figure 2A
−7.6% (95% CI, −8.8 to −6.4) with the 36-mg dose
- orforglipron 36 mg · ae_dc · Table 2
Adverse event leading to discontinuation of orforglipron or placebo 8 (5.6) 6 (4.4) 11 (7.8) 2 (1.4) 27 (4.8)
- orforglipron 36 mg · nausea · Table 2
Nausea 18 (12.6) 25 (18.2) 23 (16.3) 3 (2.2) 69 (12.3)
- orforglipron 36 mg · vomiting · Table 2
Vomiting 7 (4.9) 9 (6.6) 20 (14.2) 2 (1.4) 38 (6.8)
- orforglipron 36 mg · sae · Table 2
Any serious adverse event 8 (5.6) 7 (5.1) 4 (2.8) 5 (3.6) 24 (4.3)
- orforglipron 36 mg · hba1c · Abstract; Results, End Points
−1.48 percentage points with the 36-mg dose
- orforglipron 36 mg · disc_any · Results, Participants
and 504 par- ticipants (90.2%; 129 in the 3-mg group, 120 in the 12-mg group, 127 in the 36-mg group, and 128 in the placebo group) continued to receive orforglipron or placebo throughout the 40-week
- orforglipron 36 mg or MTD · weight_eff · Table (week 52)
52 | -8.76% | 1.66%
- orforglipron 36 mg or MTD · hba1c · Table (week 52)
Orforglipron | -1.46
- orforglipron 36 mg or MTD · disc_any · Results, disposition
2044 (74·4%) of 2749 completed the study on treatment (948 [69·1%] of 1371 assigned to orforglipron and 1096 [79·5%] of 1378 assigned to insulin glargine). The
- orforglipron 36 mg or MTD · ae_dc · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
Adverse events leading to study treatment discontinuation 211 (15·4%) 73 (5·4%)
- orforglipron 36 mg or MTD · nausea · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
Nausea 438 (31·9%) 19 (1·4%)
- orforglipron 36 mg or MTD · vomiting · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
Vomiting 288 (21·0%) 22 (1·6%)
- orforglipron 36 mg or MTD · sae · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
Serious adverse events 222 (16·2%) 255 (18·8%)
- orforglipron 3 mg · weight_unsp · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 3 mg: HbA1c -1.32; body weight -3.5 %; withdrawals for adverse events 3/240
- orforglipron 3 mg · hba1c · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 3 mg: HbA1c -1.32; body weight -3.5 %; withdrawals for adverse events 3/240
- orforglipron 3 mg · nausea · CT.gov adverse events, Other events: Nausea
"groupId": "EG000", "numEvents": 60, "numAffected": 47, "numAtRisk": 240
- orforglipron 3 mg · vomiting · CT.gov adverse events, Other events: Vomiting
"groupId": "EG000", "numEvents": 22, "numAffected": 19, "numAtRisk": 240
- orforglipron 3 mg · sae · CT.gov event groups
"id": "EG000", "title": "Orforglipron 3 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated at week 4 to a dose of 3 mg, which was then maintained up
- orforglipron 12 mg · weight_unsp · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 12 mg: HbA1c -1.74; body weight -6.3 %; withdrawals for adverse events 3/241
- orforglipron 12 mg · hba1c · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 12 mg: HbA1c -1.74; body weight -6.3 %; withdrawals for adverse events 3/241
- orforglipron 12 mg · nausea · CT.gov adverse events, Other events: Nausea
"groupId": "EG001", "numEvents": 57, "numAffected": 43, "numAtRisk": 241
- orforglipron 12 mg · vomiting · CT.gov adverse events, Other events: Vomiting
"groupId": "EG001", "numEvents": 34, "numAffected": 20, "numAtRisk": 241
- orforglipron 12 mg · sae · CT.gov event groups
"id": "EG001", "title": "Orforglipron 12 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4 and 6 mg at week 8) unti
- orforglipron 36 mg · weight_unsp · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 36 mg: HbA1c -1.73; body weight -7.3 %; withdrawals for adverse events 6/241
- orforglipron 36 mg · hba1c · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 36 mg: HbA1c -1.73; body weight -7.3 %; withdrawals for adverse events 6/241
- orforglipron 36 mg · nausea · CT.gov adverse events, Other events: Nausea
"groupId": "EG002", "numEvents": 70, "numAffected": 54, "numAtRisk": 241
- orforglipron 36 mg · vomiting · CT.gov adverse events, Other events: Vomiting
"groupId": "EG002", "numEvents": 50, "numAffected": 29, "numAtRisk": 241
- orforglipron 36 mg · sae · CT.gov event groups
"id": "EG002", "title": "Orforglipron 36 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4, 6 mg at week 8, 12 mg a
- orforglipron 6 mg · weight_tp · Abstract, Findings
mean percentage change in bodyweight was -5·9% (95% CI -7·6 to -4·2) with orforglipron 6 mg
- orforglipron 12 mg · weight_tp · Abstract, Findings
-8·7% (-10·9 to -6·5) with 12 mg
- orforglipron 36 mg · weight_tp · Abstract, Findings
and -7·9% (-10·0 to -5·8) with 36 mg
Outcome trials
Cardiovascular and kidney outcome trials
ACHIEVE-4 orforglipron 36 mg or maximum tolerated dose (oral, once daily) vs insulin glargine (active) · T2D at increased CV risk (86 % established CVD, 38 % CKD) · n = 2749 · 2026 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 4-point MACE primary MACE-4: composite of non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina, or cardiovascular death (primary endpoint; non-inferiority, safety analysis set) | 0.84 | 0.59–1.20 | 57 vs 67 | verified |
| 3-point MACE MACE-3: composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death (key secondary endpoint; superiority, randomised participants excluding GCP-closed sites) | 0.77 | 0.52–1.13 | 46 vs 59 | verified |
| Cardiovascular death Cardiovascular death (component of MACE-4; deaths of undetermined cause counted as CV deaths) | 0.47 | 0.25–0.90 | 14 vs 29 | verified |
| Myocardial infarction Non-fatal myocardial infarction (component of MACE-4) — non-fatal events only | 0.85 | 0.46–1.58 | 19 vs 22 | verified |
| Stroke Non-fatal stroke (component of MACE-4) — non-fatal events only | 0.98 | 0.47–2.06 | 14 vs 14 | verified |
| Hospitalisation for unstable angina Hospitalisation for unstable angina (component of MACE-4) | 1.55 | 0.67–3.58 | 14 vs 9 | verified |
Verbatim quotes (6)
- 4-point MACE · Table 2
p value MACE-4 (primary endpoint)* 57/1358 (4·2%) 67/1343 (5·0%) 0·84 (0·59-1·20)
- 3-point MACE · Table 2
47-2·06) ·· Hospitalisation for unstable angina 14/1358 (1·0%) 9/1343 (0·7%) 1·55 (0·67-3·58) ·· MACE-3 (key secondary endpoint)* 46/1358 (3·4%) 59/1366 (4·3%) 0·77 (0·52-1·13)
- Cardiovascular death · Table 2
p value MACE-4 (primary endpoint)* 57/1358 (4·2%) 67/1343 (5·0%) 0·84 (0·59-1·20) <0·0001 (non- inferiority) Cardiovascular death 14/1358 (1·0%) 29/1343 (2·2%) 0·47 (0·25-0·90)
- Myocardial infarction · Table 2
<0·0001 (non- inferiority) Cardiovascular death 14/1358 (1·0%) 29/1343 (2·2%) 0·47 (0·25-0·90) ·· Non-fatal myocardial infarction 19/1358 (1·4%) 22/1343 (1·6%) 0·85 (0·46-1·58)
- Stroke · Table 2
343 (2·2%) 0·47 (0·25-0·90) ·· Non-fatal myocardial infarction 19/1358 (1·4%) 22/1343 (1·6%) 0·85 (0·46-1·58) ·· Non-fatal stroke 14/1358 (1·0%) 14/1343 (1·0%) 0·98 (0·47-2·06)
- Hospitalisation for unstable angina · Table 2
(1·6%) 0·85 (0·46-1·58) ·· Non-fatal stroke 14/1358 (1·0%) 14/1343 (1·0%) 0·98 (0·47-2·06) ·· Hospitalisation for unstable angina 14/1358 (1·0%) 9/1343 (0·7%) 1·55 (0·67-3·58)
Other indications
ATTAIN-OSA trial 1 / trial 2 Orforglipron · Obstructive sleep apnoea + obesity or overweight (no T2D) · 52 weeks · n = 712 abstract
AHI −13.2 (trial 1, no PAP) and −12.0 (trial 2, on PAP) events/h vs placebo at 52 weeks, treatment-regimen estimand; 6 of 7 key secondary end points significant.
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Apnea-hypopnea index, change from baseline (treatment-regimen estimand) ATTAIN-OSA Trial 1, no PAP week 52 | −17.8 | −4.5 | −13.2 (−17.7 to −8.7) events/h | abstract |
| Apnea-hypopnea index, change from baseline (treatment-regimen estimand) ATTAIN-OSA Trial 2, on PAP week 52 | −17.3 | −5.3 | −12.0 (−17.1 to −6.9) events/h | abstract |
Verbatim quotes (2)
- Apnea-hypopnea index, change from baseline (treatment-regimen estimand)
in trial 1, the mean AHI change was -17.8 for orforglipron compared with -4.5 for placebo (difference, -13.2 [95% CI, -17.7 to -8.7]; P < .001)
- Apnea-hypopnea index, change from baseline (treatment-regimen estimand)
In trial 2, the mean AHI change was -17.3 for orforglipron and -5.3 for placebo (difference, -12.0 [95% CI, -17.1 to -6.9]; P < .001)
Ongoing outcome trials
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| Orforglipron CVOT | Orforglipron | Atherosclerotic CVD, obesity or T2D ASCVD and/or CKD with obesity or T2D | MACE | 7140 | recruiting | 2031-08 | NCT07241390 |
Registered trials (27)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| ATTAIN-CN A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems | Obesity | Phase 3 | not yet recruiting | 2026-12 → 2028-03 | 192 | not yet recruiting | NCT07790861 |
| ATTAIN-NOW A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Obesity | Phase 3 | recruiting | 2026-08 → 2029-08 | 2001 | recruiting | NCT07794579 |
| ACHIEVE-RAM A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | T2D | Phase 3 | recruiting | 2026-07 → 2027-05 | 130 | recruiting | NCT07613307 |
| ACHIEVE-PEDS A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes | T2D | Phase 3 | recruiting | 2026-07 → 2030-03 | 170 | recruiting | NCT07668336 |
| Orforglipron CVOT A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | CV outcomes | Phase 3 | recruiting | 2025-12 → 2031-08 | 7140 | NCT07241390 | |
| ATTAIN-PAD Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | CV outcomes | Phase 3 | recruiting | 2025-10 → 2028-06 | 1205 | recruiting | NCT07223593 |
| ATTAIN-OA PAIN A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Knee OA | Phase 3 | active not recruiting | 2025-09 → 2028-04 | 800 | active not recruiting | NCT07153471 |
| RESTRAIN-SUI A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight | Obesity | Phase 3 | recruiting | 2025-09 → 2028-03 | 1000 | recruiting | NCT07202884 |
| NCT06972459 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Obesity | Phase 3 | active not recruiting | 2025-05 → 2027-08 | 800 | active not recruiting | NCT06972459 |
| NCT06972472 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Obesity | Phase 3 | active not recruiting | 2025-05 → 2027-08 | 600 | active not recruiting | NCT06972472 |
| NCT06993792 A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Obesity | Phase 3 | active not recruiting | 2025-05 → 2027-08 | 1400 | active not recruiting | NCT06993792 |
| ATTAIN-HYPERTENSION A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | Hypertension | Phase 3 | active not recruiting | 2025-04 → 2027-09 | 974 | active not recruiting | NCT06948422 |
| ATTAIN-HYPERTENSION A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | Hypertension | Phase 3 | active not recruiting | 2025-04 → 2027-09 | 487 | active not recruiting | NCT06948435 |
| ATTAIN-HYPERTENSION A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | Hypertension | Phase 3 | active not recruiting | 2025-04 → 2027-09 | 487 | active not recruiting | NCT06952530 |
| ADVANCE A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Obesity | Phase 3 | recruiting | 2024-11 → 2027-02 | 125 | recruiting | NCT06672549 |
| NCT06672939 A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | Obesity | Phase 3 | recruiting | 2024-11 → 2027-12 | 150 | recruiting | NCT06672939 |
| ATTAIN-OSA trial 1 / trial 2 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | CV outcomes | Phase 3 | completed | 2024-10 → 2026-07 | 712 | Completed; results not yet public | NCT06649045 |
| ATTAIN-MAINTAIN A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Obesity | Phase 3 | completed | 2024-09 → 2025-11 | 376 | Completed; results not in the atlas yet | NCT06584916 |
| ACHIEVE-2 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin | T2D | Phase 3 | completed | 2024-01 → 2025-09 | 962 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06192108 |
| ACHIEVE-5 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | T2D | Phase 3 | completed | 2023-11 → 2025-09 | 546 | Completed; results not in the atlas yet | NCT06109311 |
| ACHIEVE-J A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2023-09 → 2025-06 | 401 | Completed; results not in the atlas yet | NCT06010004 |
| ACHIEVE-3 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | T2D | Phase 3 | completed | 2023-09 → 2025-08 | 1698 | Completed; results not in the atlas yet | NCT06045221 |
| ACHIEVE-1 A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | T2D | Phase 3 | completed | 2023-08 → 2025-04 | 559 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05971940 |
| ATTAIN-J A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease | Obesity | Phase 3 | completed | 2023-07 → 2025-06 | 238 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05931380 |
| ATTAIN-1 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Obesity | Phase 3 | active not recruiting | 2023-06 → 2025-07 | 3127 | active not recruiting | NCT05869903 |
| ATTAIN-2 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Obesity | Phase 3 | completed | 2023-06 → 2025-08 | 1613 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05872620 |
| ACHIEVE-4 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | CV outcomes | Phase 3 | completed | 2023-04 → 2026-03 | 2749 | 4-point MACE HR 0.84 (0.59–1.20) vs insulin glargine: non-inferior | NCT05803421 |
Primary sources
- Eli Lilly and Company. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) (ATTAIN-1). ClinicalTrials.gov identifier NCT05869903. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05869903
- Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. PMID: 40960239.
- Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. PMID: 41275875.
- Eli Lilly and Company. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) (ATTAIN-2). ClinicalTrials.gov identifier NCT05872620. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05872620
- Eli Lilly and Company. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (ACHIEVE-1). ClinicalTrials.gov identifier NCT05971940. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05971940
- Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065-1076. PMID: 40544435.
- Klein KR, Wysham C, Tuttle KR, Davies MJ, Cox D, Chen J, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026. PMID: 42815506.
- Eli Lilly and Company. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2) (ACHIEVE-2). ClinicalTrials.gov identifier NCT06192108. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06192108
- Yokote K, Yamauchi T, Shingaki T, Chin R, Oura T, Nagai Y, et al. Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2026. PMID: 42962687.
- Eli Lilly and Company. A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4). ClinicalTrials.gov identifier NCT05803421. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05803421
- Malhotra A, Gottlieb DJ, Woehrle H, Dennehy EB, Calamai G, Liu Z, et al. Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA). JAMA. 2026. PMID: 43002161.
- Eli Lilly and Company. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (ATTAIN-OSA). ClinicalTrials.gov identifier NCT06649045. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06649045
- Eli Lilly and Company. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. ClinicalTrials.gov identifier NCT07241390. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07241390
How to cite this page
Cite the primary publication for any single result; every value above links to it.